Welcome to our dedicated page for Adc Therapeutics Sa SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADC Therapeutics SA (NYSE: ADCT) SEC filings page brings together the company’s U.S. regulatory disclosures, offering investors structured access to its official communications. ADC Therapeutics is a commercial-stage oncology company focused on antibody drug conjugates, led by its CD19-directed therapy ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
In its recent Form 8-K filings, the company has reported preliminary revenue and cash estimates, updated clinical data from the LOTIS-7 Phase 1b trial of ZYNLONTA combinations, and the availability of corporate presentations. Other 8-Ks describe private placement agreements, unregistered sales of equity securities, and quarterly financial result announcements via attached press releases. These filings also confirm that ADC Therapeutics’ common shares trade on the New York Stock Exchange under the symbol ADCT.
Through this page, users can review filings that explain how ZYNLONTA’s accelerated and conditional approvals are being supported by confirmatory trials such as LOTIS-5 and LOTIS-7, as well as documents detailing capital-raising activities and other material events. Forms related to results of operations, material agreements, and investor presentations help clarify the company’s financial condition, clinical strategy, and risk disclosures.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points from lengthy filings, such as major clinical milestones, revenue commentary, or financing terms. Real-time updates from EDGAR, combined with simplified views of 8-Ks and other reports, allow investors researching ADCT to quickly understand what each filing means without reading every line. This makes it easier to follow ADC Therapeutics’ regulatory history, clinical progress, and corporate transactions over time.
ADC Therapeutics SA released an updated corporate presentation and furnished it as an exhibit to a current report. The presentation is attached as Exhibit 99.1 and is meant to provide investors and other stakeholders with more detail about the company and its activities. The company notes that this material is being furnished under Regulation FD, which is designed to ensure fair disclosure of information. The presentation and related information are not treated as formally filed financial statements and are not automatically incorporated into other securities law filings unless specifically referenced.
ADC Therapeutics SA reported that it has released preliminary estimates for its revenue for the quarter and year ended December 31, 2025, along with preliminary cash and cash equivalents as of that date. These figures were disclosed in a press release dated January 8, 2026, which is attached as an exhibit.
The company emphasized that these revenue and cash numbers are preliminary, unaudited and based on management’s complex judgments and estimates. Actual results for the quarter and full year 2025 are not yet finalized or reviewed by independent auditors and may differ materially from these early estimates. The information is being furnished for disclosure purposes and is not deemed filed under the securities laws unless specifically incorporated by reference.
ADC Therapeutics SA reported a routine insider equity transaction by its Chief Executive Officer and director, Ameet Mallik. On 12/06/2025, 233,146 common shares were withheld by the company at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this tax-withholding event, Mallik beneficially owns 1,319,101 common shares directly. This type of Form 4 event reflects administrative handling of equity compensation rather than an open‑market purchase or sale.
ADC Therapeutics SA reported an insider equity transaction involving its Chief Medical Officer, Mohamed Zaki. On 12/06/2025, the company withheld 41,068 common shares at a price of $3.29 per share to cover his tax withholding obligations tied to previously granted restricted share units that vested. After this automatic withholding, Zaki beneficially owns 421,820 common shares, held directly. This type of transaction reflects routine share withholding for taxes rather than an open-market sale.
ADC Therapeutics SA's Chief Accounting Officer reported a routine share transaction under Form 4. On 12/06/2025, the officer had 7,140 common shares disposed of at $3.29 per share, coded as an "F" transaction. This represents shares withheld by the company to cover tax obligations related to the vesting of previously granted restricted share units.
After this withholding event, the officer directly beneficially owns 70,757 common shares of ADC Therapeutics SA. The filing reflects administrative tax settlement activity rather than an open-market buy or sell decision.
ADC Therapeutics SA reported an insider transaction by Chief Legal Officer Peter Graham. On 12/06/2025, the company withheld 49,508 common shares at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this withholding, Graham beneficially owns 359,034 common shares directly. The filing notes that this is a routine tax withholding transaction rather than an open‑market sale, and no derivative securities transactions were reported.
ADC Therapeutics SA's Chief Financial Officer, Jose Carmona, reported a routine share withholding related to equity compensation. On 12/06/2025, the company withheld 53,236 common shares to cover his tax obligations arising from the vesting of previously granted restricted share units. The shares were valued at $3.29 per share for this tax withholding event.
After this transaction, Carmona beneficially owned 488,656 common shares, held directly. The filing is a standard Form 4 disclosure of insider equity activity rather than an open-market purchase or sale.
ADC Therapeutics SA filed Amendment No. 1 to its shelf registration statement as an exhibit-only update to include a new auditor consent from PricewaterhouseCoopers SA. The company states that this amendment does not change any part of the prospectus and consists only of the facing page, an explanatory note, Part II, signatures, the exhibit index and the new exhibit.
The company estimates total offering-related expenses of $71,341.46, including a SEC registration fee of $8,341.46, legal and accounting fees and printing costs. ADC Therapeutics will bear its own registration expenses, while any selling shareholders would be responsible for brokerage commissions or similar charges if they sell shares under the registration. The filing also restates standard Swiss-law based indemnification provisions for directors and officers and includes customary Securities Act undertakings.
ADC Therapeutics SA reported new clinical data from its ongoing LOTIS-7 Phase 1b open-label trial. This study evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma, a difficult-to-treat blood cancer. As of the November 17, 2025 cutoff date, 49 patients were considered efficacy evaluable, each with at least six months of follow-up from the start of treatment. These updated data help further characterize how this drug combination performs in heavily pretreated lymphoma patients.
ADC Therapeutics (ADCT): Schedule 13G/A—Prosight Management and affiliated reporting persons disclosed beneficial ownership of 7,195,374 common shares, representing 5.8% of the class, with shared voting and dispositive power over those shares and no sole power. The event date is 09/30/2025. The percentage is based on 123,877,111 shares outstanding as of October 31, 2025.
Within the group, Prosight Fund holds 350,415 shares (0.3%) and Prosight Plus Fund holds 1,586,895 shares (1.3%). The filing certifies the securities were not acquired for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
